Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on January 29, 2019. The report details a specific corporate event regarding the unregistered sale of equity securities.
Key Financial Metrics
The filing discloses a capital raise event but does not provide comprehensive financial statements such as revenue, profit, cash flow, or debt levels.
- Capital Raised: $1.5 million
- Shares Issued: 815,217 shares of Class A common stock
- Price Per Share: $1.84
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the execution of a provision within the December 2018 Letter Agreement, allowing the Company to require the Investor to purchase additional shares. This transaction increased the Company's cash position by $1.5 million and diluted existing shareholders through the issuance of new Class A common stock.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the December 2018 Letter Agreement. No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the terms of the December 2018 Letter Agreement referenced in the filing.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's subsequent Form 10-K for the year ending December 31, 2018, where the Letter Agreement is filed as an exhibit.
- Check for any additional unregistered sales of equity securities under similar agreements.